PL3144318T3 - Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację - Google Patents
Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilacjęInfo
- Publication number
- PL3144318T3 PL3144318T3 PL16194925T PL16194925T PL3144318T3 PL 3144318 T3 PL3144318 T3 PL 3144318T3 PL 16194925 T PL16194925 T PL 16194925T PL 16194925 T PL16194925 T PL 16194925T PL 3144318 T3 PL3144318 T3 PL 3144318T3
- Authority
- PL
- Poland
- Prior art keywords
- alpha
- sialylation
- recombinant fsh
- fsh including
- including alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4542408P | 2008-04-16 | 2008-04-16 | |
| EP08251528 | 2008-04-25 | ||
| EP13193214.7A EP2722339A1 (en) | 2008-04-16 | 2009-04-16 | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation |
| EP16194925.0A EP3144318B1 (en) | 2008-04-16 | 2009-04-16 | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation |
| EP09733497.3A EP2268666B1 (en) | 2008-04-16 | 2009-04-16 | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation |
| PCT/GB2009/000978 WO2009127826A1 (en) | 2008-04-16 | 2009-04-16 | Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3144318T3 true PL3144318T3 (pl) | 2021-02-08 |
Family
ID=39717519
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16194925T PL3144318T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację |
| PL16158141T PL3045471T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację |
| PL16179121.5T PL3098234T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację |
| PL21212873.0T PL4015527T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację |
| PL09733497T PL2268666T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację |
| PL14178729T PL2808340T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16158141T PL3045471T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację |
| PL16179121.5T PL3098234T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację |
| PL21212873.0T PL4015527T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację |
| PL09733497T PL2268666T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację |
| PL14178729T PL2808340T3 (pl) | 2008-04-16 | 2009-04-16 | Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US8951967B2 (OSRAM) |
| EP (7) | EP3098234B1 (OSRAM) |
| JP (7) | JP2011519359A (OSRAM) |
| KR (5) | KR102108377B1 (OSRAM) |
| CN (3) | CN105906702A (OSRAM) |
| AR (1) | AR071479A1 (OSRAM) |
| AU (5) | AU2009237479B2 (OSRAM) |
| BR (1) | BRPI0910461B8 (OSRAM) |
| CA (1) | CA2725257A1 (OSRAM) |
| CY (1) | CY1115413T1 (OSRAM) |
| DK (6) | DK3144318T3 (OSRAM) |
| ES (5) | ES2610277T3 (OSRAM) |
| FI (4) | FI3098234T3 (OSRAM) |
| FR (3) | FR17C1020I2 (OSRAM) |
| HR (5) | HRP20241187T1 (OSRAM) |
| HU (9) | HUE068565T2 (OSRAM) |
| IL (2) | IL208538A (OSRAM) |
| LT (8) | LT3045471T (OSRAM) |
| MX (3) | MX2010011343A (OSRAM) |
| NO (4) | NO2017025I1 (OSRAM) |
| NZ (1) | NZ588381A (OSRAM) |
| PL (6) | PL3144318T3 (OSRAM) |
| PT (6) | PT3098234T (OSRAM) |
| RU (3) | RU2537268C2 (OSRAM) |
| SA (1) | SA109300228B1 (OSRAM) |
| SI (6) | SI4015527T1 (OSRAM) |
| TW (1) | TWI488640B (OSRAM) |
| WO (1) | WO2009127826A1 (OSRAM) |
| ZA (1) | ZA201007373B (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| HRP20150968T4 (hr) | 2010-09-29 | 2023-11-10 | Ferring B.V. | Pripravak za uporabu za liječenje neplodnosti |
| KR101898302B1 (ko) | 2010-10-15 | 2018-09-13 | 제이씨알 파마 가부시키가이샤 | 당사슬의 비환원 말단이 만노오스 잔기인 당 단백질의 제조 방법 |
| CA2831486A1 (en) * | 2011-03-31 | 2012-10-04 | Ferring B.V. | Pharmaceutical preparation |
| AR090095A1 (es) | 2011-06-06 | 2014-10-22 | Ferring Bv | Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| AU2012340501A1 (en) * | 2011-12-19 | 2013-07-11 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| WO2013161958A1 (ja) * | 2012-04-27 | 2013-10-31 | 日本ケミカルリサーチ株式会社 | 新規な発現ベクター |
| EP2824176A1 (en) * | 2013-07-11 | 2015-01-14 | Siamed'xpress | Methods for producing sialylated therapeutic proteins |
| JP6652334B2 (ja) | 2014-05-31 | 2020-02-19 | Jcrファーマ株式会社 | ウリジンとn−アセチル−d−マンノサミンとを含有する培地 |
| JP2018500934A (ja) * | 2014-12-22 | 2018-01-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cmp依存性シアリダーゼ活性 |
| ES2784625T3 (es) | 2015-04-17 | 2020-09-29 | Ferring Bv | FSH para el tratamiento de la infertilidad |
| EP3313859B1 (en) | 2015-06-26 | 2019-11-20 | Ferring BV | Methods of purification and/or viral inactivation |
| EP3205719A1 (en) * | 2016-02-15 | 2017-08-16 | CEVEC Pharmaceuticals GmbH | Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| EP3382014A1 (en) * | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
| EP3441471A1 (en) | 2017-08-08 | 2019-02-13 | CEVEC Pharmaceuticals GmbH | Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines |
| AR112541A1 (es) | 2017-09-01 | 2019-11-06 | Ferring Bv | Composición para estimulación ovárica controlada con hef recombinante |
| EP3787667B1 (en) | 2018-04-30 | 2025-03-26 | Ferring B.V. | Composition for controlled ovarian stimulation |
| TWI846743B (zh) | 2018-10-17 | 2024-07-01 | 荷蘭商菲林公司 | 用於控制性卵巢刺激之組成物及方法 |
| US20220380785A1 (en) * | 2019-11-01 | 2022-12-01 | The University Of British Columbia | Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
| US20250241993A1 (en) | 2022-04-01 | 2025-07-31 | Ferring B.V. | Mixed protocol for treatment of infertility |
| US20250333466A1 (en) | 2022-05-26 | 2025-10-30 | Ferring B.V. | Compositions and methods for treatment of infertility in males |
| AU2023302100A1 (en) | 2022-07-08 | 2025-01-02 | Ferring B.V. | Compositions and methods for intrauterine insemination (iui) |
| TW202504578A (zh) | 2023-07-20 | 2025-02-01 | 荷蘭商輝凌責任有限公司 | 緩釋載藥微粒 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| US5541083A (en) | 1989-10-24 | 1996-07-30 | The Regents Of The University Of California | Method for producing secretable glycosyltransferases and other golgi processing enzymes |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| JP3559652B2 (ja) * | 1996-06-25 | 2004-09-02 | グローリー工業株式会社 | 売上精算システムの管理装置 |
| IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| JP2001507215A (ja) | 1997-01-16 | 2001-06-05 | サイテル コーポレイション | 組換え糖タンパク質のインビトロでの実用的なシアリル化 |
| JPH1111665A (ja) | 1997-06-28 | 1999-01-19 | Shibuya Kogyo Co Ltd | 無菌エア搬送コンベヤ装置 |
| TWI235158B (en) * | 1997-09-01 | 2005-07-01 | Kirin Brewery | Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same |
| EP1176976B2 (en) | 1999-05-07 | 2015-10-21 | Laboratoires Serono SA | Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women |
| JP2002011665A (ja) | 2000-06-28 | 2002-01-15 | Sintokogio Ltd | ショットブラスト装置モニタシステム |
| IL140110A0 (en) | 2000-12-05 | 2002-02-10 | Applied Research Systems | Improvement of homogeneity and secretion of recombinant proteins in mammalian systems |
| EP1621549A3 (en) * | 2001-10-22 | 2006-03-01 | Applied Research Systems ARS Holding N.V. | Compositions of fsh with high sialylation degree and their use for the preparation of medicinaments |
| BR0213402A (pt) | 2001-10-29 | 2004-10-13 | Crucell Holland Bv | Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero |
| CA2468957C (en) | 2001-12-07 | 2011-07-12 | Crucell Holland B.V. | Methods of propagation of influenza virus in cell lines over expressing sialyl transferases |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| US20080015142A1 (en) * | 2003-12-03 | 2008-01-17 | Defrees Shawn | Glycopegylated Follicle Stimulating Hormone |
| DK1711834T3 (da) | 2004-02-04 | 2010-11-29 | Centre Nat Rech Scient | Fremgangsmåde til screening af glycoform-specifikke antistoffer |
| CN1926242B (zh) | 2004-02-13 | 2013-01-16 | 格莱克托普有限公司 | 高活性糖蛋白加工条件及其有效生产方法 |
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| WO2012016575A1 (en) | 2010-08-03 | 2012-02-09 | King Saud University | Stoma coat |
| WO2012016576A1 (en) * | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| HRP20150968T4 (hr) | 2010-09-29 | 2023-11-10 | Ferring B.V. | Pripravak za uporabu za liječenje neplodnosti |
| CA2831486A1 (en) | 2011-03-31 | 2012-10-04 | Ferring B.V. | Pharmaceutical preparation |
| AR090095A1 (es) | 2011-06-06 | 2014-10-22 | Ferring Bv | Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| US20170035854A1 (en) | 2014-04-18 | 2017-02-09 | Glycotope Gmbh | Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone |
-
2009
- 2009-04-15 TW TW098112483A patent/TWI488640B/zh active
- 2009-04-16 SI SI200932209T patent/SI4015527T1/sl unknown
- 2009-04-16 ES ES14178729.1T patent/ES2610277T3/es active Active
- 2009-04-16 LT LTEP16158141.8T patent/LT3045471T/lt unknown
- 2009-04-16 HU HUE16179121A patent/HUE068565T2/hu unknown
- 2009-04-16 EP EP16179121.5A patent/EP3098234B1/en active Active
- 2009-04-16 LT LTEP14178729.1T patent/LT2808340T/lt unknown
- 2009-04-16 CN CN201510933782.9A patent/CN105906702A/zh active Pending
- 2009-04-16 PT PT161791215T patent/PT3098234T/pt unknown
- 2009-04-16 PL PL16194925T patent/PL3144318T3/pl unknown
- 2009-04-16 PL PL16158141T patent/PL3045471T3/pl unknown
- 2009-04-16 BR BRPI0910461A patent/BRPI0910461B8/pt active IP Right Grant
- 2009-04-16 DK DK16194925.0T patent/DK3144318T3/da active
- 2009-04-16 ES ES16158141.8T patent/ES2629392T3/es active Active
- 2009-04-16 EP EP13193214.7A patent/EP2722339A1/en active Pending
- 2009-04-16 KR KR1020197022294A patent/KR102108377B1/ko active Active
- 2009-04-16 DK DK14178729.1T patent/DK2808340T3/en active
- 2009-04-16 LT LTEP21212873.0T patent/LT4015527T/lt unknown
- 2009-04-16 PT PT212128730T patent/PT4015527T/pt unknown
- 2009-04-16 PT PT141787291T patent/PT2808340T/pt unknown
- 2009-04-16 KR KR1020167012148A patent/KR20160056960A/ko not_active Ceased
- 2009-04-16 EP EP16194925.0A patent/EP3144318B1/en active Active
- 2009-04-16 HU HUE14178729A patent/HUE030652T4/en unknown
- 2009-04-16 AU AU2009237479A patent/AU2009237479B2/en active Active
- 2009-04-16 ES ES09733497.3T patent/ES2468318T3/es active Active
- 2009-04-16 DK DK16158141.8T patent/DK3045471T3/en active
- 2009-04-16 CA CA2725257A patent/CA2725257A1/en active Pending
- 2009-04-16 ES ES21212873T patent/ES3023526T3/es active Active
- 2009-04-16 JP JP2011504527A patent/JP2011519359A/ja active Pending
- 2009-04-16 HR HRP20241187TT patent/HRP20241187T1/hr unknown
- 2009-04-16 EP EP14178729.1A patent/EP2808340B1/en not_active Revoked
- 2009-04-16 DK DK16179121.5T patent/DK3098234T3/da active
- 2009-04-16 MX MX2010011343A patent/MX2010011343A/es active IP Right Grant
- 2009-04-16 SI SI200930931T patent/SI2268666T1/sl unknown
- 2009-04-16 NZ NZ588381A patent/NZ588381A/en unknown
- 2009-04-16 ES ES16179121T patent/ES2989729T3/es active Active
- 2009-04-16 SI SI200932094T patent/SI3144318T1/sl unknown
- 2009-04-16 MX MX2017007881A patent/MX355457B/es unknown
- 2009-04-16 PL PL16179121.5T patent/PL3098234T3/pl unknown
- 2009-04-16 US US12/988,218 patent/US8951967B2/en active Active
- 2009-04-16 CN CN200980121391XA patent/CN102066414A/zh active Pending
- 2009-04-16 HR HRP20140535AT patent/HRP20140535T1/hr unknown
- 2009-04-16 WO PCT/GB2009/000978 patent/WO2009127826A1/en not_active Ceased
- 2009-04-16 DK DK21212873.0T patent/DK4015527T3/da active
- 2009-04-16 PT PT161581418T patent/PT3045471T/pt unknown
- 2009-04-16 KR KR1020177026920A patent/KR20170110741A/ko not_active Ceased
- 2009-04-16 FI FIEP16179121.5T patent/FI3098234T3/fi active
- 2009-04-16 PL PL21212873.0T patent/PL4015527T3/pl unknown
- 2009-04-16 KR KR1020187023820A patent/KR20180095140A/ko not_active Ceased
- 2009-04-16 KR KR1020107025581A patent/KR101622944B1/ko active Active
- 2009-04-16 SI SI200931547A patent/SI2808340T1/sl unknown
- 2009-04-16 RU RU2010141908/10A patent/RU2537268C2/ru active
- 2009-04-16 HR HRP20250313TT patent/HRP20250313T1/hr unknown
- 2009-04-16 PL PL09733497T patent/PL2268666T3/pl unknown
- 2009-04-16 EP EP16158141.8A patent/EP3045471B1/en not_active Revoked
- 2009-04-16 EP EP09733497.3A patent/EP2268666B1/en not_active Revoked
- 2009-04-16 EP EP21212873.0A patent/EP4015527B1/en active Active
- 2009-04-16 RU RU2014141994A patent/RU2682270C2/ru active
- 2009-04-16 FI FIEP21212873.0T patent/FI4015527T3/fi active
- 2009-04-16 CN CN201510933827.2A patent/CN105906703A/zh active Pending
- 2009-04-16 SI SI200931670A patent/SI3045471T1/sl unknown
- 2009-04-16 LT LTEP16179121.5T patent/LT3098234T/lt unknown
- 2009-04-16 DK DK09733497.3T patent/DK2268666T3/da active
- 2009-04-16 PT PT97334973T patent/PT2268666E/pt unknown
- 2009-04-16 SI SI200932205T patent/SI3098234T1/sl unknown
- 2009-04-16 PT PT161949250T patent/PT3144318T/pt unknown
- 2009-04-16 PL PL14178729T patent/PL2808340T3/pl unknown
- 2009-04-16 MX MX2014011348A patent/MX348622B/es unknown
- 2009-04-16 HU HUE21212873A patent/HUE071059T2/hu unknown
- 2009-04-16 AR ARP090101333A patent/AR071479A1/es not_active Application Discontinuation
- 2009-04-16 HU HUE16158141A patent/HUE033830T2/en unknown
- 2009-04-18 SA SA109300228A patent/SA109300228B1/ar unknown
-
2010
- 2010-10-07 IL IL208538A patent/IL208538A/en active Protection Beyond IP Right Term
- 2010-10-14 ZA ZA2010/07373A patent/ZA201007373B/en unknown
-
2014
- 2014-01-21 IL IL230571A patent/IL230571A/en active IP Right Grant
- 2014-06-06 CY CY20141100402T patent/CY1115413T1/el unknown
- 2014-06-17 AU AU2014203277A patent/AU2014203277C1/en active Active
- 2014-11-14 US US14/541,852 patent/US9546204B2/en active Active
- 2014-12-25 JP JP2014262056A patent/JP2015120696A/ja active Pending
-
2016
- 2016-08-16 US US15/238,362 patent/US9771407B2/en active Active
- 2016-10-07 JP JP2016198588A patent/JP6486310B2/ja active Active
- 2016-11-16 HR HRP20161520TT patent/HRP20161520T1/hr unknown
-
2017
- 2017-05-30 HU HUS1700024C patent/HUS1700024I1/hu unknown
- 2017-05-31 HU HUS1700025C patent/HUS1700025I1/hu unknown
- 2017-06-05 LT LTPA2017018C patent/LTPA2017018I1/lt unknown
- 2017-06-06 FR FR17C1020C patent/FR17C1020I2/fr active Active
- 2017-06-06 NO NO2017025C patent/NO2017025I1/no unknown
- 2017-06-23 AU AU2017204258A patent/AU2017204258B2/en active Active
- 2017-06-23 AU AU2017204259A patent/AU2017204259B2/en active Active
- 2017-06-26 HR HRP20170958TT patent/HRP20170958T1/hr unknown
- 2017-08-01 JP JP2017148823A patent/JP6762916B2/ja active Active
- 2017-08-29 US US15/690,061 patent/US10995128B2/en active Active
- 2017-09-05 AU AU2017225020A patent/AU2017225020B2/en active Active
- 2017-09-27 HU HUS1700036C patent/HUS1700036I1/hu unknown
- 2017-09-27 LT LTPA2017029C patent/LTPA2017029I1/lt unknown
- 2017-09-28 NO NO2017050C patent/NO2017050I1/no unknown
-
2018
- 2018-11-08 RU RU2018139379A patent/RU2745557C3/ru active Protection Beyond IP Right Term
-
2019
- 2019-10-25 JP JP2019194476A patent/JP7316905B2/ja active Active
-
2021
- 2021-04-30 US US17/246,348 patent/US11952407B2/en active Active
- 2021-10-27 JP JP2021175403A patent/JP2022031652A/ja active Pending
-
2023
- 2023-12-21 JP JP2023215339A patent/JP2024038000A/ja active Pending
-
2024
- 2024-03-14 US US18/605,381 patent/US20240327487A1/en active Pending
-
2025
- 2025-01-15 FI FIC20250003C patent/FIC20250003I1/fi unknown
- 2025-01-16 FR FR25C1003C patent/FR25C1003I1/fr active Active
- 2025-01-16 NO NO2025006C patent/NO2025006I1/no unknown
- 2025-01-24 LT LTPA2025505C patent/LTPA2025505I1/lt unknown
- 2025-01-28 HU HUS2500008C patent/HUS2500008I1/hu unknown
- 2025-07-02 FR FR25C1025C patent/FR25C1025I1/fr active Active
- 2025-07-07 LT LTPA2025525C patent/LTPA2025525I1/lt unknown
- 2025-07-07 HU HUS2500029C patent/HUS2500029I1/hu unknown
- 2025-07-11 FI FIC20250025C patent/FIC20250025I1/fi unknown
- 2025-07-14 NO NO2025032C patent/NO2025032I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500029I1 (hu) | Alfa 2,3- és alfa 2,6-szalizációt tartalmazó rekombináns FSH | |
| PL3581631T3 (pl) | Kompozycje zawierające 2,3,3,3-tetrafluoropropen | |
| IL211762A0 (en) | Pegylated opiods, compositions comprising the same and uses thereof | |
| SI2356123T1 (sl) | Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni | |
| ZA201005346B (en) | 3,8-diaminotetrahydroquinoline derivative | |
| AP2010005388A0 (en) | Pupicidal and larvicidal composition. | |
| IL207174A0 (en) | Peptides, compositions, and uses thereof | |
| HUE051918T2 (hu) | Alfa 2,3- és alfa 2,6-szialilációt tartalmazó rekombináns FSH | |
| GB0808401D0 (en) | Fsh | |
| GB0813815D0 (en) | Corcost Pre 1001,10 | |
| GB0809709D0 (en) | Dunhill car,2093 | |
| GB0705503D0 (en) | The buffer |